Author

H. Mirza

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:mouse· 2 Assay:proteomics· 2

Frequent Co-Authors

I. McNeish· 3 shared D. Ennis· 2 shared P. Roxburgh· 2 shared Z. Cheng· 2 shared A. Biankin· 1 shared A. DeFazio· 1 shared A. Han· 1 shared A. Iwasaki· 1 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

I. McNeish

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Inflammasome activation in infected macrophages drives COVID-19 pathology

E. Sefik, R. Qu, C. Junqueira, E. Kaffe, H. Mirza, J. Zhao, J. R. Brewer, A. Han, H. R. Steach, B. Israelow, H. N. Blackburn, S. Velazquez, Y. G. Chen, S. Halene, A. Iwasaki, , R. A. Flavell

This study shows SARS-CoV-2 infection of human macrophages drives COVID-19 pathology through inflammasome activation, leading to inflammation and pyroptosis, but also enabling viral release.

bioRxiv · Sep 27, 2021Immunology

Dual G9A and EZH2 inhibition stimulates an anti-tumour immune response in ovarian high-grade serous carcinoma

P. Spiliopoulou, S. Spear, H. Mirza, I. Garner, L. Mcgarry, F. Grundland-Freile, Z. Cheng, D. Ennis, S. McNamara, M. Natoli, S. Mason, K. Blyth, P. Adams, P. Roxburgh, M. Fuchter, , I. McNeish

This study shows that dual inhibition of G9A and EZH2 in ovarian cancer enhances anti-tumour immune responses by altering the immune microenvironment and reducing tumour growth.

bioRxiv · May 9, 2021Cancer Biology

The genomic landscape of early stage ovarian high grade serous carcinoma

Z. Cheng, H. Mirza, D. P. Ennis, P. Smith, L. Morrill, C. Sokota, G. Giannone, T. Goranova, T. Bradley, A. Piskorz, M. Lockley, The BriTROC Investigators, B. Kaur, N. Singh, L. Tookman, , I. McNeish

This study compares genomic features of early and late stage high grade serous ovarian carcinoma, finding no unique mutations or focal copy number alterations but noting differences in ploidy and copy number signatures.

bioRxiv · May 5, 2021Cancer Biology

Ovarian carcinosarcoma genomics and pre-clinical models highlight the N-MYC pathway as a key driver and susceptibility to EMT-targeting therapy

G. Y. Ho, E. Kyran, J. Bedo, M. Wakefield, D. Ennis, H. Mirza, S. Cooke, E. Lieschke, C. Vandenberg, O. Kondrashova, R. Upstill-Goddard, U.-M. Bailey, S. Biankin, P. Roxburgh, R. Glasspool, , H. Barker

This study identifies N-MYC pathway activation and susceptibility to EMT-targeting therapy in ovarian carcinosarcoma using genomic and pre-clinical models.

bioRxiv · Nov 24, 2020 · PreprintCancer Biology